Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03764735 · ClinicalTrials.gov registry record · Phase 3
Study of SkQ1 as Treatment for Dry-eye Syndrome
A Phase 3 study of Dry Eye Syndrome, sponsored by Mitotech.
- Completed
- Registry status
- Phase 3
- Development phase
- 452
- Enrollment target
- 7
- Study locations
NCT03764735 is a Phase 3 study of Dry Eye Syndrome that has completed, run by Mitotech. The registered enrollment target is 452 participants, above the 120-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (277% higher). The trial reports 7 study locations across 7 states.
The verdict
NCT03764735, a Phase 3 study of Dry Eye Syndrome, has completed, sponsored by Mitotech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 452 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
Conditions Studied
Interventions
- DRUG Low Dose - SkQ1
- DRUG High dose - SkQ1
- DRUG SkQ1 (Vehicle)
Study Locations (7)
Arizona
- Cornea & Cataract Consultants of Arizona - Phoenix
California
- Eye Research Foundation - Newport Beach
Kentucky
- Eye Care Insititute - Louisville
Maine
- Central Maine Eye Care - Lewiston
Massachusetts
- Andover Eye Associates - Andover
North Carolina
- Vita Eye Clinic - Shelby
Tennessee
- Total Eye Care, PA - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 452 participants |
| Start Date | 2018-12-06 |
| Est. Completion | 2019-02-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03764735
The ClinicalTrials.gov registry entry for NCT03764735 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 452 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 120-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (277% higher). The listed sponsor is Mitotech, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Low Dose - SkQ1 is the first listed.
NCT03764735 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT03764735 about?
NCT03764735 is a clinical study titled "Study of SkQ1 as Treatment for Dry-eye Syndrome". The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
What is the current status of trial NCT03764735?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 452 participants. The study started on 2018-12-06. Estimated completion is 2019-02-09.
What conditions does trial NCT03764735 study?
This clinical trial studies the following conditions: Dry Eye Syndrome.
What interventions are being tested in trial NCT03764735?
The interventions under investigation include: Low Dose - SkQ1 (DRUG), High dose - SkQ1 (DRUG), SkQ1 (Vehicle) (DRUG).
Who is sponsoring clinical trial NCT03764735?
This trial is sponsored by Mitotech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03764735 being conducted?
This trial has 7 study locations across Arizona, California, Kentucky, Maine, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome
COMPLETED · Phase 3
-
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
RECRUITING · Phase 1
-
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
COMPLETED · NA
-
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye
COMPLETED · Phase 2
-
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
COMPLETED · Phase 1
-
Effects of Dry Eye Treatments on the Ocular Surface
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.